<p>股票分拆有時可以成為公司在股票周圍製造激動的有效方式。這是公司運營良好的標誌，通過分拆降低股票價格，股票可以更容易地被更廣泛的投資者羣體所接觸。這就是為什麼股票分拆後股價通常會上漲。</p>
<p>一個股價開始接近 1000 美元的股票是 <strong>禮來</strong>(LLY -3.82%)。其股價接近 1000 美元，公司可能有理由進行股票分拆，或許在今年早些時候就會有。投資者是否應該期待近期會有股票分拆呢？</p>
<h2>禮來 上次進行股票分拆是在 1997 年</h2>
<p>這家醫療保健公司幾十年來沒有進行股票分拆；它最後一次分拆是在 1997 年進行的 2 比 1 的分拆。雖然那確實是很久以前的事情，可以説禮來並沒有必要進行分拆。直到 2018 年，該股票甚至還沒有交易超過 100 美元。</p>
<p>但在過去幾年裏，禮來的股票價格一直在飆升。在五年內，該股票的回報率接近 800%。它已成為全球市值最高的醫療保健股票，並且看起來有望在未來加入萬億美元俱樂部，目前市值約為 8500 億美元。</p>
<h2>禮來進行股票分拆是否是必然的？</h2>
<p>禮來的股價已經足夠高，進行股票分拆是有道理的。但這並不意味着一定會進行分拆。</p>
<p><strong>Chipotle Mexican Grill</strong> 最近進行了股票分拆，其股價在決定進行分拆之前約為 3000 美元。股價遠低於這個價格的股票也進行了分拆。去年，禮來的競爭對手 <strong>Novo Nordisk</strong> 進行了 2 比 1 的股票分拆，儘管其股價不到 200 美元。</p>
<p>最終，這取決於管理層。在關於股票分拆的公告實際發生之前，投資者只能猜測是否會發生。</p>
<p>沒有保證禮來會在今年或未來五年內分拆其股票。畢竟，股票分拆並不是必要的。即使股價超過 1000 美元，股票仍然有可能升值。擁有零頭股份使投資者能夠投資於一家企業，無論其股價有多高。</p>
<h2>無論是否進行股票分拆，禮來都是一個很好的買入選擇</h2>
<p>有許多投資禮來的理由，包括其有前途的增長前景。由於其有前途的減肥和糖尿病治療藥物 Zepbound 和 Mounjaro，該公司一直在產生令人印象深刻的營收和利潤增長。從長遠來看，它們有潛力為公司創造數百億美元的收入，因為禮來已經在火熱的抗肥胖治療市場中確立了自己的領先地位。</p>
<p>由於公司長期業務潛力巨大，儘管估值很高，禮來可能是一個很棒的投資。目前，其市盈率接近 140。</p>
<p>雖然股票分拆可能會帶來一些激動，但這並不是投資禮來的理由。無論是否進行股票分拆，該股票都有可能升值。</p>

禮來

<p>禮來（Eli Lilly）的股價接近 1000 美元，引發了關於可能進行股票分拆的猜測。雖然該公司自 1997 年以來沒有進行過股票分拆，但股價最近的激增以及未來增長潛力使其成為一項有前途的投資，無論是否進行股票分拆。最終決定在於管理層，目前並不能保證近期會進行股票分拆</p>

<p>Stock splits can sometimes be an effective way for a company to generate excitement around its stock. It's a sign that the company is doing well, and by lowering the price of the stock through a split, the shares can become more accessible to a wider pool of investors. It's why shares often rally following a stock split.</p>
<div class="lb-trans"><p>股票分拆有時可以成為公司在股票周圍製造激動的有效方式。這是公司運營良好的標誌，通過分拆降低股票價格，股票可以更容易地被更廣泛的投資者羣體所接觸。這就是為什麼股票分拆後股價通常會上漲。</p>
</div><p>One stock that's starting to get up there in price is <strong>Eli Lilly</strong>(LLY -3.82%). Its shares are getting close to $1,000, and there could be a case for the company to deploy a stock split, perhaps as early as this year. Should investors expect one in the near future?</p>
<div class="lb-trans"><p>一個股價開始接近 1000 美元的股票是 <strong>禮來</strong>(LLY -3.82%)。其股價接近 1000 美元，公司可能有理由進行股票分拆，或許在今年早些時候就會有。投資者是否應該期待近期會有股票分拆呢？</p>
</div><h2>Eli Lilly last did a stock split in 1997</h2>
<div class="lb-trans"><h2>禮來 上次進行股票分拆是在 1997 年</h2>
</div><p>The healthcare company hasn't done a stock split in decades; its last one was a 2-for-1 back in 1997. While that's definitely a long time ago, there arguably hasn't been the <em>need</em> for Eli Lilly to do one. Until 2018, the stock wasn't even trading above $100.</p>
<div class="lb-trans"><p>這家醫療保健公司幾十年來沒有進行股票分拆；它最後一次分拆是在 1997 年進行的 2 比 1 的分拆。雖然那確實是很久以前的事情，可以説禮來並沒有必要進行分拆。直到 2018 年，該股票甚至還沒有交易超過 100 美元。</p>
</div><p>But in the past few years, shares of Eli Lilly have been taking off. In five years, the stock has generated returns of nearly 800%. It has become the most valuable healthcare stock in the world and looks like it's on track to join the trillion-dollar club in the future with its market cap currently around $850 billion.</p>
<div class="lb-trans"><p>但在過去幾年裏，禮來的股票價格一直在飆升。在五年內，該股票的回報率接近 800%。它已成為全球市值最高的醫療保健股票，並且看起來有望在未來加入萬億美元俱樂部，目前市值約為 8500 億美元。</p>
</div><h2>Is a stock split inevitable for Eli Lilly?</h2>
<div class="lb-trans"><h2>禮來進行股票分拆是否是必然的？</h2>
</div><p>Eli Lilly's stock price is high enough that doing a stock split would make sense. But that doesn't mean one is coming.</p>
<div class="lb-trans"><p>禮來的股價已經足夠高，進行股票分拆是有道理的。但這並不意味着一定會進行分拆。</p>
</div><p><strong>Chipotle Mexican Grill</strong> recently did a stock split, and its share price was around $3,000 before it decided to do so. Stocks at much lower prices have done splits, as well. Last year, Eli Lilly's rival <strong>Novo Nordisk</strong> deployed a 2-for-1 stock split even though its share price was less than $200.</p>
<div class="lb-trans"><p><strong>Chipotle Mexican Grill</strong> 最近進行了股票分拆，其股價在決定進行分拆之前約為 3000 美元。股價遠低於這個價格的股票也進行了分拆。去年，禮來的競爭對手 <strong>Novo Nordisk</strong> 進行了 2 比 1 的股票分拆，儘管其股價不到 200 美元。</p>
</div><p>Ultimately, it comes down to management. Until an announcement about a stock split actually takes place, investors can only speculate about whether it will or won't happen.</p>
<div class="lb-trans"><p>最終，這取決於管理層。在關於股票分拆的公告實際發生之前，投資者只能猜測是否會發生。</p>
</div><p>There are no guarantees that Eli Lilly will split its shares this year or even five years from now. Stock splits aren't a necessity, after all. A stock can rise in value even if its share price is north of $1,000. Owning fractional shares makes it possible for investors to invest in a business regardless of how high its stock price is.</p>
<div class="lb-trans"><p>沒有保證禮來會在今年或未來五年內分拆其股票。畢竟，股票分拆並不是必要的。即使股價超過 1000 美元，股票仍然有可能升值。擁有零頭股份使投資者能夠投資於一家企業，無論其股價有多高。</p>
</div><h2>Eli Lilly is a great buy whether or not it splits its stock</h2>
<div class="lb-trans"><h2>無論是否進行股票分拆，禮來都是一個很好的買入選擇</h2>
</div><p>There are many great reasons to invest in Eli Lilly -- including its promising growth prospects. The company has been generating impressive revenue and profit growth due to Zepbound and Mounjaro, its promising weight loss and diabetes treatments. They have the potential to generate tens of billions in revenue for the company in the long run, as Eli Lilly has established itself as an early leader in the scorching-hot market for anti-obesity treatments.</p>
<div class="lb-trans"><p>有許多投資禮來的理由，包括其有前途的增長前景。由於其有前途的減肥和糖尿病治療藥物 Zepbound 和 Mounjaro，該公司一直在產生令人印象深刻的營收和利潤增長。從長遠來看，它們有潛力為公司創造數百億美元的收入，因為禮來已經在火熱的抗肥胖治療市場中確立了自己的領先地位。</p>
</div><p>With so much potential for the business in the long run, Eli Lilly could be a fantastic investment, despite its high valuation. It currently trades at a price-to-earnings multiple of nearly 140.</p>
<div class="lb-trans"><p>由於公司長期業務潛力巨大，儘管估值很高，禮來可能是一個很棒的投資。目前，其市盈率接近 140。</p>
</div><p>While a stock split may generate some excitement, it's not a reason to invest in Eli Lilly. The stock is likely to rise in value regardless of whether it splits its shares or not.</p>
<div class="lb-trans"><p>雖然股票分拆可能會帶來一些激動，但這並不是投資禮來的理由。無論是否進行股票分拆，該股票都有可能升值。</p>
</div>

禮來公司會在 2024 年進行股票拆分嗎？